Remed Co.Ltd vs Abbott Laboratories: Fair Value & Quality
Both stocks run through our valuation models. Here is how Remed Co.Ltd (302550) and Abbott Laboratories (ABT) compare, as of Aug 11, 2026.
As of Aug 11, 2026, Fair Value Calculator sees Abbott Laboratories as the less overvalued of the two: Remed Co.Ltd trades at KRW 2,960 versus a fair value of KRW 454 (-85%), while Abbott Laboratories trades at $108 versus $74.79 (-31%).
Remed Co.Ltd
302550.KQ · KRW · Health Care
-85%
upside to fair value
overvalued
PriceKRW 2,960
Fair ValueKRW 454
Quality49/100
Abbott Laboratories
ABT · USD · Health Care
-31%
upside to fair value
overvalued
Price$108
Fair Value$74.79
Quality67/100
Head-to-head numbers
Green value = the better side for that row (for valuation multiples: lower = cheaper).
Remed Co.LtdAbbott Laboratories
Valuation
—P/E (TTM)27.7×
—P/S (TTM)3.89×
—P/B3.36×
—EV/EBITDA15.1×
—PEG1.47×
Profitability
5%Net margin14%
10%Operating margin13%
2%Return on equity12%
1%Return on assets6%
Growth
11%Revenue growth (YoY)8%
4.7%Avg. growth/yr (3Y)0.5%
8.1%Avg. growth/yr (5Y)5.1%
Balance & size
0.07×Debt / equity0.19×
$57MMarket cap$175B
mixedGrowth qualityhealthy
Even match: 4 to 4 metric wins.
Dash = not meaningfully computable, for example with negative equity.
Quality in detail
The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.
Remed Co.Ltdof which business quality 50 · market factors 38Abbott Laboratoriesof which business quality 66 · market factors 51
ProfitabilityMargins and returns on capital today
27
50
Quality GrowthAre margins and returns improving?
34
47
CashflowEarnings quality: real cash, not paper profit
InvestmentDisciplined investing over empire-building
80
65
Low VolatilityCalm price path (market factor)
59
83
MomentumPrice trend over the last 3–12 months (market factor)
32
40
52W MomentumDistance to the 52-week high (market factor)
24
33
Net IssuanceBuybacks instead of dilution
36
84
What the models say
The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.
Remed Co.Ltd
DCF ModelsKRW 914
Earnings-BasedKRW 306
MultiplesKRW 442
Asset-BasedKRW 887
Growth DCFKRW 990
Economic ProfitKRW 641
Growth EarningsKRW 316
24 of 24 models see the stock below the current price.
Abbott Laboratories
DCF Models$73.01
Earnings-Based$29.42
Dividend Discount$39.73
Multiples$70.72
Asset-Based$20.05
Growth DCF$67.02
Economic Profit$37.49
Growth Earnings$70.25
26 of 26 models see the stock below the current price.
Scenario ranges
From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.
Remed Co.Ltd
Bear KRW 245Fair Value KRW 454Bull KRW 491
KRW 2,960 = current price (white tick)
Abbott Laboratories
Bear $51.84Fair Value $74.79Bull $94.43
$108 = current price (white tick)
Compare two other stocks
Tap a field and type again, ticker or company name.
Free, no sign-up
Ranked within their sector
Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.
Remed Co.Ltd · Health Care
Quality score49 · below median
Fair value upside-85% · bottom 25%
Abbott Laboratories · Health Care
Quality score67 · Top 25%
Fair value upside-31% · below median
Bottom line
As of Aug 11, 2026, Fair Value Calculator sees Abbott Laboratories as the less overvalued of the two: Remed Co.Ltd trades at KRW 2,960 versus a fair value of KRW 454 (-85%), while Abbott Laboratories trades at $108 versus $74.79 (-31%).
Abbott Laboratories has the higher quality score (67/100).
Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.
A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.
